Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $80.15 Consensus PT from Analysts

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) have received an average rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $80.1538.

Several brokerages have weighed in on VERA. HC Wainwright dropped their target price on Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, August 12th. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Raymond James Financial reiterated a “strong-buy” rating on shares of Vera Therapeutics in a research report on Tuesday. Bank of America lifted their price objective on shares of Vera Therapeutics from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Finally, Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a research report on Wednesday, July 8th.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the business’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer owned 151,994 shares of the company’s stock, valued at $6,429,346.20. The trade was a 23.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 83,250 shares of company stock worth $3,307,800. 15.90% of the stock is owned by insiders.

Institutional Trading of Vera Therapeutics

A number of hedge funds have recently modified their holdings of the company. Eversept Partners LP lifted its holdings in shares of Vera Therapeutics by 9.4% during the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after acquiring an additional 264,468 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Vera Therapeutics by 9.3% in the 4th quarter. Geode Capital Management LLC now owns 1,444,925 shares of the company’s stock worth $73,185,000 after acquiring an additional 123,350 shares in the last quarter. Armistice Capital LLC boosted its stake in Vera Therapeutics by 22.0% in the fourth quarter. Armistice Capital LLC now owns 653,796 shares of the company’s stock worth $33,108,000 after purchasing an additional 117,796 shares in the last quarter. First Turn Management LLC lifted its position in Vera Therapeutics by 69.7% during the 4th quarter. First Turn Management LLC now owns 601,774 shares of the company’s stock worth $30,474,000 after buying an additional 247,245 shares in the last quarter. Finally, Elmind Capital LP bought a new stake in shares of Vera Therapeutics during the fourth quarter valued at approximately $24,434,000. Institutional investors own 99.21% of the company’s stock.

Key Headlines Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: TRUTAKNA met all prespecified primary and secondary endpoints in the 104-week ORIGIN 3 trial for primary IgA nephropathy. The treatment stabilized kidney function, improved eGFR versus placebo and reduced the risk of a composite kidney-disease progression event by 76%. Vera Therapeutics ORIGIN 3 final analysis
• Positive Sentiment: Vera plans to submit a supplemental Biologics License Application in the fourth quarter of 2026, potentially positioning TRUTAKNA for full FDA approval in 2027. The company also reported more than 350 patient start forms during the first 10 weeks of the commercial launch, suggesting early demand. Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
• Positive Sentiment: The company described TRUTAKNA’s safety profile as generally comparable to placebo, with similar overall adverse-event and infection rates in the trial. Vera kidney drug Trutakna shows strong final results
• Neutral Sentiment: Options activity was unusually high, with traders purchasing 3,132 call contracts—about twice the average volume—indicating heightened speculative interest but not guaranteeing further gains.
• Negative Sentiment: Despite the favorable data, VERA reversed its early advance and moved lower, likely reflecting profit-taking and investor caution after the initial announcement. TRUTAKNA remains under accelerated approval, so continued approval depends on verification of clinical benefit in additional regulatory review. Vera Stock Slides Despite Positive Phase 3 Results
• Negative Sentiment: TRUTAKNA carries immune-related risks, including infections and injection-site reactions, which could affect prescribing, patient uptake and the pace of commercial growth.

Vera Therapeutics Trading Down 1.1%

NASDAQ:VERA opened at $33.67 on Friday. The company has a market cap of $2.43 billion, a PE ratio of -5.75 and a beta of 0.96. The business’s 50 day moving average is $34.80 and its two-hundred day moving average is $37.03. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. Vera Therapeutics has a 52 week low of $23.05 and a 52 week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($1.58) by $0.06. During the same quarter in the prior year, the business posted ($1.20) EPS. On average, analysts predict that Vera Therapeutics will post -6.44 EPS for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms.

Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand.